Physician profile
Michael William Dotti
NPI 1497718936
$1,009.08
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $323 · 2021: $124.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $474.95 | 2019-2021 | |
| Glaxosmithkline, LLC. | $108.18 | 2019-2021 | |
| Amarin Pharma, INC. | $67.39 | 2019-2020 | |
| Allergan, INC. | $63.41 | 2019 | |
| Amgen INC. | $55.06 | 2019 | |
| Abbvie INC. | $41.15 | 2019-2021 | |
| Novo Nordisk INC | $37.83 | 2019 | |
| Astellas Pharma US INC | $28.41 | 2019-2020 | |
| Grt US Holding, INC. | $25.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.01 | 2019 | |
| Antares Pharma, INC. | $20.78 | 2020 | |
| Genentech USA, INC. | $20.45 | 2020 | |
| Strongbridge US INC. | $14.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.13 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.39 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dotti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.